Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A small Stanford study found that low-dose naltrexone helped long COVID patients feel and function better, with notable drops in fatigue, brain fog, and post-exertional malaise. The catch? No control group means natural recovery or other treatments could explain the gains. Researchers are calling for randomized controlled trials before drawing firm conclusions.
A retrospective cohort study presented at IDWeek found that low-dose naltrexone (LDN) — an off-label use of an FDA-approved opioid antagonist — was associated with meaningful symptom relief in 230 long COVID patients treated at Stanford's Long COVID Clinic. Over the follow-up period, patients reported significant reductions in fatigue, brain fog, unrefreshing sleep, difficulty sleeping, and post-exertional malaise, alongside improved functional status scores.
The findings are encouraging given that long COVID currently has no FDA-approved treatments, and several prior candidates — including Paxlovid — have failed to beat placebo in trials. Researchers believe LDN may work through anti-inflammatory and immunomodulatory mechanisms, which could make it a logical fit for long COVID's complex pathophysiology. That said, the study's observational design and absence of a control group are significant limitations — natural disease progression or concurrent therapies could explain some of the improvements.
By the Numbers:
Why it matters: With millions of Americans affected by long COVID and no approved therapies, even preliminary signals like these are clinically significant — but randomized controlled trials are urgently needed to confirm whether LDN offers genuine benefit beyond natural recovery.
